Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditi…
An institutional-grade, numbers-driven thesis on MRNA — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Moderna, Inc. (MRNA) 53/100 with a 12-month base-case forecast of $46.11 — -14.4% versus the current price of $53.86. Moderna, Inc. trades at $53.86 in the Healthcare sector, with a market capitalisation of $21.37B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for MRNA is $46.11, implying -14.4% versus the current price. The model's 12-month scenario range runs from $73.91 (bear) to $91.85 (bull), with a base case of $81.24.
On the fundamentals, Moderna shows a P/E of -6.7, trailing revenue of $1.94B, revenue growth of -39.2% YoY. This page also tracks MRNA's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
MRNA currently carries a TradersQuant composite score of 53/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $46.11 implies -14.4% from $53.86. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for MRNA is $46.11, about -14.4% versus the latest price of $53.86. Consensus is based on 27 analysts.
TradersQuant's 12-month model forecast for MRNA is a base case of $81.24, ranging from $73.91 (bear) to $91.85 (bull), an expected return of +50.8%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for MRNA over the next 12 months is $81.24 in the base case (bear $73.91, bull $91.85), versus today's price of $53.86. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for MRNA — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates MRNA's fair value at $46.11, implying -14.4% of expected upside versus the current price.
Moderna does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
